X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

iKnowMed EHR and iKnowMed Generation 2 EHR Receive 2015 ONC-ACB Certification

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System

Content Team by Content Team
5th January 2018
in Americas, News

McKesson Specialty Health, an industry leader in services and technologies that advance community-based healthcare, announced that iKnowMedSM electronic health record (EHR) (version 6.8) and iKnowMed Generation 2 EHR (version 3.0) have received ONC-ACB 2015 Edition Certification. These products, with the support of My Care PlusSM patient portal (version 3.13) and Practice InsightsSM analytics , were certified as “Meaningful Use-ready” to support practices participating in value-based care. In addition to the many clinical and operational benefits these technologies bring to practices, providers using iKnowMed are eligible for bonus points in the Quality Performance category under the Merit-based Incentive Payment System (MIPS).

The products were tested and certified through the Drummond Group’s Electronic Health Records Office of the National Coordinator Authorized Certification Body (ONC-ACB) program and are now certified as 2015 Edition compliant. Practices utilizing iKnowMed can demonstrate Meaningful Use in 2015, helping them avoid penalties under the American Recovery and Reinvestment Act while making them eligible for incentive payments under MIPS.

Combining the advanced technologies of McKesson Specialty Health with expertise from physicians in The US Oncology Network, these leading-edge technology products provide unique support for practices, enabling them to efficiently respond to the ever-changing requirements of the value-based environment while delivering high-quality care to patients. The products incorporate the latest interoperability standards, facilitating seamless exchange of patient information with other electronic systems, including EHRs at collaborating practices and hospitals.

“Our 2015 Edition certified products are leading the way in value-based care solutions, providing efficient technologies that drive better care and care coordination, support improved clinical and business decisions, and enhance patient engagement,” said Dan Lodder, vice president and general manager, Technology Solutions, McKesson Specialty Health. “Additionally, practices using iKnowMed are eligible to collect incentive dollars by attesting to Meaningful Use in 2015 and beyond, contributing to the financial success of the practice.”

The iKnowMed EHR team is committed to providing superior service and support for community-based providers, enabling practices to quickly and efficiently implement new technologies to meet Meaningful Use requirements while maximizing incentives available through MIPS. In 2015 and 2016, more than 90% of practices using iKnowMed in both The US Oncology Network and McKesson’s Onmark Select Program were successful in attesting to Meaningful Use. This provided $6.9 million in iKnowMed incentive payments to affiliated practices in 2015 and 2016.

“Maintaining compliance in today’s dynamic regulatory landscape is increasingly challenging for community-based oncology practices,” said Marcus Neubauer, M.D., vice president and medical director, Payer and Clinical Services, McKesson Specialty Health. “McKesson’s Meaningful Use certified technologies play a vital role in enabling practices to keep up to date with the changing healthcare landscape, allowing them to efficiently and successfully implement the changes that are vital to succeed in value-based care.”

About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, works together with stakeholders across the healthcare delivery system to preserve and strengthen specialty care, passionately driven by the benefits it provides patients and the system as a whole. Through innovative provider, practice management, biopharma and payer solutions, McKesson Specialty Health focuses on improving the financial, operational and business health of our customers and partners so they may provide the best care to patients. At McKesson Specialty Health, we believe that we are all in this together. For more information, visit www.mckessonspecialtyhealth.com

About The US Oncology Network
Every day, The US Oncology Network helps more than 1,400 independent physicians deliver value-based, integrated care for patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network provides doctors with access to coordinated resources, best business practices, and the experience, infrastructure and support of McKesson Specialty Health. This collaboration allows the doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. Together, The Network and its affiliated physicians are committed to the success of independent practices, everywhere. For more information, visit www.usoncology.com

PR Contact
Claire Crye
281-825-9927
Claire.Crye@McKesson.com

Previous Post

ThriveRx Wins ASPEN Clinical Nutrition Team of Distinction Award

Next Post

MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix® Injectable for Achilles Tendonitis

Related Posts

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Next Post

MiMedx Announces the Enrollment of the First Patients in the Phase 3 Clinical Trial of AmnioFix® Injectable for Achilles Tendonitis

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In